Time course of adverse events in patients with localization-related epilepsy receiving topiramate added to carbamazepine

Epilepsia

Volumn 46, Issue 5, 2005, Pages 648-653

  Majkowski, Jerzy ^a   Neto, Walter ^b   Wapenaar, Robert ^c   Van Oene, Joop ^c,d  

^a Foundation of Epileptology   (Poland)

^b JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

^c Janssen Cilag BV Netherlands   (Netherlands)

^d Janssen EMEA   (Netherlands)

Author keywords

Antiepileptic drug; Carbamazepine; Polytherapy; Side effects; Time course; Topiramate

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; PLACEBO; TOPIRAMATE;

ADULT; AGED; ANOREXIA; ANTICONVULSANT THERAPY; ARTICLE; CLINICAL TRIAL; COGNITIVE DEFECT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG WITHDRAWAL; EPILEPSY; FATIGUE; FEMALE; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NERVOUSNESS; PARESTHESIA; PRIORITY JOURNAL; SEIZURE; SIDE EFFECT; SOMNOLENCE; TITRIMETRY; UPPER RESPIRATORY TRACT INFECTION; VERTIGO; WEIGHT REDUCTION;

ADOLESCENT; ADULT; AGED; ANTICONVULSANTS; ANXIETY; CARBAMAZEPINE; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; EATING DISORDERS; EPILEPSIES, PARTIAL; FEMALE; FRUCTOSE; HEADACHE; HUMANS; INCIDENCE; MALE; META-ANALYSIS; MIDDLE AGED; PARESTHESIA; PLACEBOS; RANDOMIZED CONTROLLED TRIALS; SLEEP DISORDERS; TIME FACTORS; WEIGHT LOSS;

EID: 18244371918     PISSN: 00139580     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1528-1167.2005.35904.x     Document Type: Article

References (28)

1. Faught E, Wilder BJ, Ramsay RE, et al. Topiramate placebo-controlled dose-ranging trial in refractory epilepsy using 200-, 400-, and 600-mg daily dosages: Topiramate YD Study Group. Neurology 1996;46:1684-90.
2. Privitera MD, Fincham R, Penry J, et al. Topiramate placebo-controlled dose-ranging trial in refractory partial epilepsy using 600-, 800-, and 1000-mg daily dosages: Topiramate YD Study Group. Neurology 1996;46:1678-83.
3. Sharief M, Viteri C, Ben-Menachem E, et al. Double-blind, placebo-controlled study of topiramate in patients with refractory partial epilepsy. Epilepsy Res 1996;25:217-24.
4. Tassinari CA, Michelucci R, Chauvel P, et al. Double-blind, placebo-controlled trial of topiramate (600 mg daily) for the treatment of refractory partial epilepsy. Epilepsia 1996;37:763-8.
5. Ben-Menachem E, Henriksen O, Dam M, et al. Double-blind, placebo-controlled trial of topiramate as add-on therapy in patients with refractory partial seizures. Epilepsia 1996;37:539-43.
6. Biton V, Edwards KR, Montouris GD, et al. Topiramate titration and tolerability. Ann Pharmacother 2001;35:173-9.
7. Yen DJ, Yu HJ, Guo YC, et al. A double-blind, placebo-controlled study of topiramate in adult patients with refractory partial epilepsy. Epilepsia 2000;41:1162-6.
8. Gilliam FG, Veloso F, Bomhof MAM, et al. A dose-comparison trial of topiramate as monotherapy in recently diagnosed partial epilepsy. Neurology 2003;60:196-202.
9. Privitera MD, Brodie MJ, Mattson RH, et al. Topiramate, carbamazepine and valproate monotherapy: double-blind comparison in newly diagnosed epilepsy. Acta Neurol Scand 2003;107:165-75.
10. Stephen LJ, Sills GJ, Brodie MJ. Topiramate in refractory epilepsy: a prospective observational study. Epilepsia 2000;41:977-80.
11. Dodson WE, Kamin M, Kraut M, et al. Topiramate titration to response: analysis of individualized therapy study (TRAITS). Ann Pharmacother 2003;37:615-20.
12. Reife RA, Pledger GW, Wu SC. Topiramate as add-on therapy: pooled analysis of randomized controlled trials in adults. Epilepsia 2000;41(suppl 1):S66-71.
13. Guberman A, Neto W, Gassman-Mayer C, et al. Low-dose topiramate in adults with treatment-resistant partial-onset seizures. Acta Neurol Scand 2002;106:183-9.
14. Greenwood RS. Adverse effects of antiepileptic drugs. Epilepsia 2000;41(suppl 2):S42-52.
15. Brandes JL, Saper JR, Diamond M, et al. Topiramate for migraine prevention: a randomized controlled trial. JAMA 2004;291:965-73.
16. Silberstein SD, Neto W, Schmitt J, et al. Topiramate in migraine prevention: results of a large controlled trial. Arch Neurol 2004;61:490-5.
17. Diener H-C, Tfelt-Hansen P, Dahlöf C, et al. Topiramate in migraine prophylaxis: results from a placebo-controlled trial with propranolol as an active control. J Neurol 2004;251:943-50.
18. Shorvon SD. Safety of topiramate: adverse events and relationships to dosing. Epilepsia 1996;37(suppl. 2):S18-22.
19. Bray GA, Hollander P, Klein S, et al. A 6-month randomized, placebo-controlled, dose-ranging trial of topiramate for weight loss in obesity. Obes Res 2003;11:722-33.
20. Martin R, Kuzniecky R, Ho S, et al. Cognitive effects of topiramate, gabapentin, and lamotrigine in healthy young adults. Neurology 1999;52:321-7.
21. Meador KJ, Loring DW, Hulihan JF, et al. Differential cognitive and behavioral effects of topiramate and valproate. Neurology 2003;60:1483-8.
22. Aldenkamp AP, Baker G, Mulder OG, et al. A multicenter, randomized clinical study to evaluate the effect on cognitive function of topiramate compared with valproate as add-on therapy to carbamazepine in patients with partial-onset seizures. Epilepsia 2000;41:1167-78.
23. Ben-Menachem E, Axelsen M, Hellebö Johanson E, et al. Predictors of weight loss in adults with topiramate-treated epilepsy. Obes Res 2003;11:556-62.
24. Silberstein SD. Control of topiramate-induced paresthesias with supplemental potassium. Headache 2002;42:85.
25. Peeters K, Adriaenssen I, Wapenaar R, et al. A pooled analysis of adjunctive topiramate in refractory partial epilepsy. Acta Neurol Scand 2003;108:9-15.
26. Arroyo S, Squires L, Wang S, et al. Topiramate (TPM): effective as monotherapy in dose-response study in newly diagnosed epilepsy. Epilepsia 2002;43(suppl 7):241.
27. Young W, Hulihan J, Wu S. Characterization and time course of paresthesia associated with topiramate: data from double-blind, placebo-controlled studies of topiramate in migraine prevention. Headache 2004;44:531.
28. Majkowski J, Petrukhin A, Rajna P, et al. Incidence and time-course of adverse events during topiramate add-on to carbamazepine in patients with partial epilepsy. Epilepsia 2002;43(suppl 8):151.